A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

BMC Cancer

Shibani Nicum⁶  Corran Roberts³  Lucy Boyle⁹  Sylwia Kopijasz⁹  Charlie Gourley⁸  Marcia Hall⁵  Ana Montes⁷  Christopher Poole¹  Linda Collins⁹  Anna Schuh²  Susan J Dutton⁴ 

[1] University Hospital Coventry & Warwickshire NHS Trust, Coventry, UK

[2] Oxford University Hospitals NHS Trust, Oxford, UK

[3] Centre for Statistics in Medicine, University of Oxford, Oxford, UK

[4] Oxford Clinical Trials Research Unit (OCTRU), University of Oxford, Oxford, UK

[5] Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, Middlesex, UK

[6] Medical Oncologist, Department of Oncology, Churchill Hospital, Oxford OX3 7LJ, UK

[7] Guy's and St Thomas' NHS Foundation Trust, London, UK

[8] Edinburgh Cancer Research Centre, Edinburgh, UK

[9] OCTO – Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK

关键词: Response;    BRCA genes;    Ovarian cancer;    Breast cancer;   

Others  :  1106824
DOI  :  10.1186/1471-2407-14-983

 received in 2014-10-28, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AGO14699, even after these cells had acquired resistance to a PARP inhibitor or cisplatin. Exploiting the genetic basis of these tumours enables us to develop a more tailored approach to therapy for patients with BRCA mutated cancers.

Methods

This multi-centre phase II single arm trial was designed to investigate the activity and safety of 6-mercaptopurine (6MP) 55 mg/m² per day, and methotrexate 15 mg/m² per week in patients with advanced breast or ovarian cancer, ECOG PS 0–2, progressing after ≥ one prior regimen and known to bear a BRCA1/2 germ line mutation. Accrual was planned in two stages, with treatment continuing until progression or unacceptable toxicity; in the first, if less than 3/30 evaluable patients respond at 8 weeks after commencing treatment, the trial will be stopped for futility; if not, then accrual would proceed to a second stage, in which if more than 9/65 evaluable patients are found to respond at 8 weeks, the treatment will be regarded as potentially effective and a phase III trial considered subject to satisfactory safety and tolerability. The primary outcome is objective response at 8 weeks, defined by RECISTS v1.1 as complete response, partial response or stable disease. Secondary outcomes include safety, progression- free and overall survival, and quality of life.

Discussion

This study aims to investigate whether 6MP might be an effective treatment for BRCA deficient tumours even after the development of resistance to PARP inhibitors or platinum drugs. The study has surpassed the first stage analysis criteria of more than 3 out of 30 evaluable patients responding at 8 weeks, and is currently in the second stage of recruitment.

Trial registration

NCT01432145http://www.ClinicalTrials.gov webcite

【 授权许可】

   
2014 Nicum et al.; licensee BioMed Central.

【 参考文献 】

• [1]Ozol RJ: Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006, 17(5):v181-v187.
• [2]Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92:564-569.
• [3]Yang HJ, Liu VWS, Wang Y, Tsang PCK, Ngan HYS: Differential DNA methylationprofiles in gynaecological cancers and correlation with clinicopatholigical data. BMC Cancer 2006, 6:212. BioMed Central Full Text
• [4]Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Menth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434:913-917.
• [5]Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921.
• [6]Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS: Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N Engl J Med 2009, 361:123-134.
• [7]Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J: Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985, 24(3):707-713.
• [8]Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. J Cancer Res 2008, 68:2581-2586.
• [9]Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
• [10]Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
• [11]Bökkerink JP, Bakker MA, Hulscher TW, De Abreu RA, Schretlen ED: Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 1988, 37(12):2321-2327.
• [12]Bökkerink JP, Stet EH, De Abreu RA, Damen FJ, Hulscher TW, Bakker MA, van Baal JA: 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T- lymphoblasts. Biochem Pharmacol 1993, 45(7):1455-1463.
• [13]Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A: Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009, 1(6–7):323-337.
• [14]Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T: 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. J Cancer Res 2010, 70(15):6268-6276.
• [15]Jung SH, Carey M, Kim KM: Graphical search for two-stage designs for phase II clinical trials. Control Clin Trials 2001, 22(4):367-372.
• [16]Jung SH, Lee T, Kim K, George SL: Admissible two-stage designs for phase II cancer clinical trials. Stat Med 2004, 23(4):561-569.